Inflammatory molecular signature associated with infectious agents in psychosis

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 963-972

  Hayes, Lindsay N ^a   Severance, Emily G ^a   Leek, Jeffrey T ^b   Gressitt, Kristin L ^a   Rohleder, Cathrin ^c   Coughlin, Jennifer M ^a   Leweke, F Markus ^c   Yolken, Robert H ^a   Sawa, Akira ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

At risk mental status; Biomarker; Cerebrospinal fluid; Inflammation; Schizophrenia; Toxoplasma gondii

Indexed keywords

ADIPONECTIN; ALPHA 2 MACROGLOBULIN; DIPEPTIDYL CARBOXYPEPTIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRINOGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 2; STEM CELL FACTOR; STROMELYSIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTIBODY; BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN G; SIGNAL PEPTIDE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PSYCHOSIS; SCHIZOPHRENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; CLINICAL TRIAL; IMMUNOLOGY; INFLAMMATION; MULTICENTER STUDY; RISK; YOUNG ADULT;

ADULT; ANTIBODIES; BIOMARKERS; CEREBROSPINAL FLUID; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; TOXOPLASMOSIS; YOUNG ADULT;

EID: 84907337938     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu052     Document Type: Article

References (40)

1. McGrath JJ, Mortensen PB, Visscher PM, Wray NR. Where GWAS and epidemiology meet: opportunities for the simultaneous study of genetic and environmental risk factors in schizophrenia. Schizophr Bull. 2013;39: 955-959.
2. Brown AS. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol. 2012;72: 1272-1276.
3. Husted JA, Ahmed R, Chow EW, Brzustowicz LM, Bassett AS. Early environmental exposures influence schizophrenia expression even in the presence of strong genetic predisposition. Schizophr Res. 2012;137: 166-168.
4. Singh S, Kumar A, Agarwal S, Phadke SR. Genetic insight of schizophrenia: past and future perspectives. Gene. 2013;535: 97-100.
5. Leweke FM, Gerth CW, Koethe D, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254: 4-8.
6. Yolken RH, Torrey EF. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol Psychiatry. 2008;13: 470-479.
7. Meyer U, Feldon J. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res. 2009;204: 322-334.
8. Giovanoli S, Engler H, Engler A, et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science. 2013;339: 1095-1099.
9. Canetta SE, Brown AS. Prenatal infection, maternal immune activation, and risk for schizophrenia. Transl Neurosci. 2012;3: 320-327.
10. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39: 1174-1179.
11. Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry. 2014;75: 300-306.
12. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011;93: 23-58.
13. Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull. 2012;38: 642-647.
14. Arias I, Sorlozano A, Villegas E, et al. Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res. 2012;136: 128-136.
15. Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res. 2011;128: 61-65.
16. Prasad KM, Eack SM, Goradia D, et al. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. Am J Psychiatry. 2011;168: 822-830.
17. Shirts BH, Prasad KM, Pogue-Geile MF, Dickerson F, Yolken RH, Nimgaonkar VL. Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. Schizophr Res. 2008;106: 268-274.
18. García-Bueno B, Bioque M, Mac-Dowell KS, et al. Pro-/Antiinflammatory dysregulation in patients with first episode of psychosis: Toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. 2014;40: 376-387.
19. Ramsey JM, Schwarz E, Guest PC, et al. Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One. 2013;8: e78729.
20. Schwarz E, van Beveren NJ, Ramsey J, et al. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr Bull. 2013 Sep 11. [Epub ahead of print].
21. Schwarz E, Guest PC, Rahmoune H, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17: 494-502.
22. Domenici E, Willé DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010;5: e9166.
23. Huang JT, Leweke FM, Tsang TM, et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One. 2007;2: e756.
24. Holmes E, Tsang TM, Huang JT, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006;3: e327.
25. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70: 663-671.
26. Coughlin JM, Ishizuka K, Kano SI, et al. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatry. 2013;18: 10-11.
27. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67: 241-251.
28. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill-advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010;120: 23-37.
29. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res. 2001;51: 47-54.
30. Therneau TM. A Package for Survival Analysis in S. R Package Version 2.37-4; 27 March 2013. http: //CRAN.Rproject. org/package=survival
31. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer; 2003.
32. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
33. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100: 9440-9445.
34. Alonso M, Dimitrijevic A, Recuero M, Serrano E, Valdivieso F, López-Guerrero JA. Interaction of alpha-2-macroglobulin and HSV-1 during infection of neuronal cells. J Neurovirol. 2001;7: 556-563.
35. Lee CW, Bennouna S, Denkers EY. Screening for Toxoplasma gondii-regulated transcriptional responses in lipopolysaccharide-activated macrophages. Infect Immun. 2006;74: 1916-1923.
36. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320: 539-543.
37. Wolf G. "As time goes by": angiotensin II-mediated transactivation of the EGF receptor comes of age. Nephrol Dial Transplant. 2005;20: 2050-2053.
38. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/saltinduced hypertensive rats. Hypertens Res. 2005;28: 925-936.
39. Gold SM, Chalifoux S, Giesser BS, Voskuhl RR. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation. 2008;5: 32.
40. Saavedra JM. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond). 2012;123: 567-590.